• tFUS Limits Post-Stroke NLRP3 Neuroinflammation

  2026-09-25

  In a rat ischemic-stroke model and complementary microglial experiments, transcranial focused ultrasound stimulation (tFUS) improved neurological outcomes while reducing NLRP3 inflammasome activation. The study connects these effects to a Nespas/miR-383-3p/SHP2 regulatory pathway, providing a mechanistic basis for further testing of non-invasive neuromodulation in post-stroke neuroinflammation.

• AG-490 in Exosomal JAK2/STAT6 Research

  2026-09-25

  Use AG-490 to test whether exosomal SNORD52-associated macrophage changes depend on kinase signaling—not simply to label a pathway as active. This workflow pairs dose-aware inhibitor controls with exosome, phosphorylation, and polarization readouts for more interpretable hepatocellular carcinoma research.

• Catalpol Workflows for Translational Research

  2026-09-24

  Catalpol offers a practical way to test multi-pathway biology across neuroprotection, bone, stroke, and liver-fibrosis models. This guide turns the available evidence into a staged workflow for dose selection, pathway readouts, and troubleshooting—while keeping model-specific results distinct from general recommendations.

• Ginsenoside Rg6 Sensitizes Cisplatin-Resistant EOC

  2026-09-24

  A 2025 study reports that ginsenoside Rg6 reduces fucosylation and promotes autophagy in cisplatin-resistant epithelial ovarian cancer cells, with changes linked to GRB2–ERK1/2–mTOR signaling. The findings support further investigation of Rg6 as a combination-treatment candidate, while leaving key questions about dose, selectivity, and clinical translation unresolved.

• Patient-Derived Gastric Cancer Assembloids

  2026-09-23

  Shapira-Netanelov and colleagues developed gastric cancer assembloids that combine patient-matched tumor organoids with tumor-derived stromal cell populations. The models showed stromal-associated changes in gene expression and drug sensitivity, illustrating why tumor-only cultures may miss features relevant to preclinical response testing.

• Epidermal Growth Factor in MYC–TNBC Assays

  2026-09-23

  Epidermal Growth Factor is more than a proliferation reagent: it can define how MYC-driven breast cancer assays distinguish EGFR-dependent growth from drug-induced cell death. This guide integrates recombinant human EGF handling with insights from a recent EphA2 synthetic-lethality study to improve mechanistic assay design.

• ETS1–SENP2–FUNDC1 Axis in Bronchopulmonary Dysplasia

  2026-09-22

  The reference study identifies ETS1 as an upstream regulator of mitochondrial quality control in bronchopulmonary dysplasia, linking transcriptional activation of SENP2 to SUMO1-dependent FUNDC1 degradation and suppression of excessive mitophagy. Its cell and mouse hyperoxia models suggest that the ETS1–SENP2–HSPA8–FUNDC1 pathway may preserve mitochondrial homeostasis and alveolar development, although additional validation is needed before clinical translation.

• Gefitinib (ZD1839) for Reliable EGFR Assays

  2026-09-22

  This scenario-driven guide explains how Gefitinib (ZD1839), SKU A8219, can improve the interpretation and reproducibility of EGFR-focused viability, proliferation, and cytotoxicity experiments. It covers assay design, stock preparation, orthogonal validation, cross-domain applications, and practical supplier-selection criteria.

• Parathyroid hormone (1-34) (human): Lab Guide

  2026-09-21

  This scenario-based guide explains how Parathyroid hormone (1-34) (human), SKU A1129, can support controlled bone, kidney, viability, and signaling experiments. It translates receptor potency, formulation, storage, and assay-interpretation data into practical decisions for biomedical laboratories.

• Catalpol: Liver Injury Assay & Workflow Guide

  2026-09-21

  Build a mechanism-led Catalpol workflow for drug-induced liver injury, combining glucose metabolism, mitochondrial respiration, oxidative stress, and SIRT1/HIF-1α assays. The approach distinguishes pathway rescue from nonspecific cytoprotection and can be adapted cautiously to broader Catalpinoside research applications.

• HDAC Inhibition Reverses EBV-Driven NPC Dedifferentiation

  2026-09-20

  The reference study identifies an epigenetic mechanism by which EBV latent protein LMP1 drives dedifferentiation and stem-like plasticity in nasopharyngeal carcinoma. It further shows that HDAC inhibition can restore CEBPA expression and differentiation in preclinical models, supporting a mechanistically grounded form of differentiation therapy for solid tumors.

• Erlotinib as a State-Resolved EGFR Probe

  2026-09-19

  Erlotinib, also known as NSC 718781, can do more than suppress EGFR activity: it can help distinguish receptor-proximal dependence from SCUBE3-associated resistance and immune-evasion biology. This article presents an evidence-aware assay framework for interpreting kinase, proliferation, apoptosis, DNA-repair, and tumor-microenvironment readouts.

• BMS 599626 dihydrochloride Workflow Guide

  2026-09-18

  Build a rigorous EGFR/HER2 workflow around BMS 599626 dihydrochloride, from receptor phosphorylation assays to cancer cell proliferation inhibition and xenograft-oriented study design. The guide also shows how to connect pathway perturbation with senescence assays without overstating evidence for senolytic activity.

• Recombinant Human EGF for 3D Glioblastoma Assays

  2026-09-18

  Use recombinant human EGF to add a defined growth-factor variable to 3D glioblastoma spheroid experiments, from stemness screening to dose-response studies. This workflow combines validated EGF bioactivity with a streamlined 96-well assay that reduces handling, time, and contamination risk.

• Gefitinib in Gastric Cancer Assembloid Research

  2026-09-17

  Discover how Gefitinib (ZD1839) can be evaluated in patient-derived gastric cancer assembloids rather than epithelial monocultures alone. This guide connects EGFR pathway pharmacology with stromal effects, phosphosignaling, viability, apoptosis, and assay design.

7892 records 1/527 page Next 12345 下5页 Last page